ILY101

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
ILY101
Accession Number
DB05059
Type
Small Molecule
Groups
Investigational
Description

ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.

Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in kidney disease.

Pharmacodynamics
Not Available
Mechanism of action

ILY101 binds dietary phosphate in the gastrointestinal tract, facilitating excretion of phosphorus into feces. It is therefore anticipated to ameliorate hyperphosphatemia by reducing the absorption of dietary phosphate. Due to its low swelling rate after fluid absorption, less gastrointestinal adverse events, including constipation, flatulence and upper abdominal pain, are expected. Strong phosphorus binding capacity may result in the reduced number of tablets and improved compliance.

Absorption

Nonabsorbable

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347909920

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentImpaired Renal Function / Kidney Diseases1
3CompletedTreatmentChronic Kidney Disease (CKD) / Hyperphosphataemia / Impaired Renal Function / Renal Dialysis1
3CompletedTreatmentChronic Kidney Disease (CKD) / Impaired Renal Function / Renal Dialysis2
Not AvailableActive Not RecruitingNot AvailableChronic Renal Failure (CRF)1
Not AvailableCompletedNot AvailableChronic Kidney Disease (CKD)1
Not AvailableCompletedNot AvailableChronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 21, 2007 16:23 / Updated on June 04, 2019 06:14